PDF(Pubmed)
Abstract：
The pharmacodynamic substances in \"Scrophulariae Radix-Fritillaria\" and the molecular mechanisms underlying its therapeutic effects against goiter were analyzed through metabolomics and serum pharmaco-chemistry. A rat model of goiter was established using propylthiouracil (PTU), and the animals were treated using \"Scrophulariae Radix-Fritillaria.\" The efficacy of the drug pair was evaluated in terms of thyroid gland histopathology and blood biochemical indices. Serum and urine samples of the rats were analyzed by UPLC-Q-TOF/MS. Principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA) were performed to screen potential biomarkers in urine and the corresponding metabolic pathways. The blood components of \"Scrophulariae Radix-Fritillaria\" were also identified, and their correlation with urine biomarkers was analyzed in order to screen for potential bioactive compounds. \"Scrophulariae Radix-Fritillaria\" mitigated injury to thyroid tissues and normalized the levels of the thyroid hormones FT3, FT4, and TSH. We also identified 22 urine biomarkers related to goiter, of which 19 were regulated by \"Scrophulariae Radix-Fritillaria.\" Moreover, urine biomarkers are involved in tryptophan metabolism, steroid hormone biosynthesis, and beta-alanine metabolism, and these pathways may be targeted by the drug pair. In addition, 47 compounds of \"Scrophulariae Radix-Fritillaria\" were detected by serum pharmacochemistry, of which nine components, namely, syringic acid, paeonol, cedrol, and cis-ferulic acid, fetisinine, aucubigenin, linolenic acid, ussuriedine, and 5-(methylsulfanyl)pentanenitrile, were identified as potential effective substances against goiter. To summarize, we characterized the chemical components and mechanisms of \"Scrophulariae Radix-Fritillaria\" involved in the treatment of goiter, and our findings provide an experimental basis for its clinical application.
摘要：
通过代谢组学和血清药物化学分析了“玄参贝母”的药效学物质及其对甲状腺肿治疗作用的分子机制。使用丙基硫氧嘧啶（PTU）建立大鼠甲状腺肿模型，用玄参贝母处理动物。“根据甲状腺组织病理学和血液生化指标评估药物对的疗效。通过UPLC-Q-TOF/MS分析大鼠的血清和尿液样本。采用主成分分析(PCA)和正交偏最小二乘判别分析(OPLS-DA)筛选尿液中潜在的生物标志物及相应的代谢途径。还鉴定了“玄参贝母”的血液成分，并分析了它们与尿液生物标志物的相关性，以筛选潜在的生物活性化合物。“玄参贝母”减轻了对甲状腺组织的损伤，并使甲状腺激素FT3，FT4和TSH的水平正常化。我们还确定了22种与甲状腺肿相关的尿液生物标志物，其中19个受玄参贝母调节。\"此外，尿液生物标志物参与色氨酸代谢，类固醇激素生物合成，和β-丙氨酸代谢，这些途径可能是药物对的目标。此外,通过血清药物化学检测了“玄参贝母”中的47种化合物，其中九个组成部分，即,丁香酸,丹皮,cedrol,和顺式阿魏酸,fetisinine,aucubicenin,亚麻酸,ussuriedine,和5-(甲硫基)戊腈，被确定为针对甲状腺肿的潜在有效物质。总结一下,我们表征了“玄参贝母”治疗甲状腺肿的化学成分和机理，为其临床应用提供了实验依据。
